Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Marseille – page 106

1 490 clinical trials in Marseille, France across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Marseille at a glance
1 490
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

1 490 trials in Marseille

Open in trial search

Parkinson's disease

Not recruiting

Study on the Effectiveness and Safety of BIIB122 for Patients with Parkinson's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:N2-(3-(2-(2H-1,2,3-Triazol-2-Yl)Propan-2-Yl)-1-Cyclopropyl-1H-Pyrazol-5-Yl)-N4-Ethyl-5-(Trifluoromethyl)Pyrimidine-2,4-Diamine
  • Sponsor:Biogen Idec Research Limited

Hepatocellular carcinoma

Not recruiting

Study of Atezolizumab and Bevacizumab for Patients with High-Risk Hepatocellular Carcinoma After Surgery or Ablation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Malignant melanoma+1

Not recruiting

Study on the Effectiveness and Safety of Naporafenib Combinations in Patients with Previously Treated Unresectable or Metastatic Melanoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Naporafenib
  • Sponsor:Novartis Pharma AG

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of CAEL-101 with Plasma Cell Dyscrasia Treatment in Patients with Stage IIIa AL Amyloidosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anselamimab
  • Sponsor:Alexion Pharmaceuticals Inc.

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Pulmonary embolism

Not recruiting

Study on Reduced Dose of Alteplase for Patients with Intermediate-High-Risk Acute Pulmonary Embolism

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Assistance Publique Hopitaux De Paris

Factor VIII deficiency

Not recruiting

Long-Term Safety Study of Valoctocogene Roxaparvovec for Patients with Severe Hemophilia A

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Valoctocogene Roxaparvovec
  • Sponsor:Biomarin Pharmaceutical Inc.

Non-small cell lung cancer+2

Not recruiting

Study Comparing Lorlatinib and Crizotinib for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Lorlatinib
  • Sponsor:Pfizer Inc.

Rhabdomyosarcoma+4

Not recruiting

Study of Lenvatinib for Children and Young Adults with Relapsed or Refractory Solid Tumors, Including High Grade Glioma and Rhabdomyosarcoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Chronic kidney disease+1

Not recruiting

Study on Low Dose Rivaroxaban for Heart and Blood Vessel Disease in Patients with Advanced Kidney Disease or on Dialysis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban
  • Sponsor:The George Institute For Global Health

Malignant mast cell neoplasm

Not recruiting

Study of Entrectinib in Children and Adolescents with Advanced or Metastatic Solid Tumors or Primary CNS Tumors with No Satisfactory Treatment Options

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Entrectinib
  • Sponsor:F. Hoffmann-La Roche AG

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Marseille

What the registry says about research in the country

01 Oncology Research

Studies focusing on innovative treatments for head and neck squamous cell carcinoma, examining novel therapies and combinations with radiotherapy. Research includes investigations into endometrial cancer and bladder cancer treatments.

  • Advanced tumor treatments
  • Immunotherapy combinations
  • Targeted therapies

Particular emphasis on combining immunotherapy with conventional treatments for improved patient outcomes.

02 Cardiovascular and Metabolic Disorders

Innovative research addressing heart failure prevention and treatment of acute myocardial infarction. Studies include new approaches for managing hypertriglyceridemia and chronic kidney disease.

  • Preventive cardiology
  • Emergency cardiac care
  • Metabolic conditions

Focus on developing novel therapeutic approaches and improving patient outcomes in cardiovascular health.

03 Neurological Conditions

Clinical investigations into multiple sclerosis treatment strategies and management of essential tremor. Research includes innovative approaches for Dravet Syndrome and neurological disorders.

  • Movement disorders
  • Autoimmune conditions
  • Seizure management

Emphasis on developing targeted therapies for various neurological conditions affecting both adults and children.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.